Obesity and metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials.

287Background: Previous findings regarding the correlation between body mass index (BMI) and survival in patients with prostate cancer are conflicting and may be disease-state dependent. We aimed to test whether BMI among patients with metastatic prostate cancer (mCRPC) is associated with overall survival (OS) and cancer-specific mortality (CSM). Methods: We identified 1577 patients with mCRPC from the control arms of 3 randomized trials. The role of BMI was investigated both as a continuous and categorical variable ( 30 km/m2). A BMI > 30 kg/m2 was considered obese. Analyses were adjusted for age, PSA, ECOG, # of metastasis and prior treatment. A Cox semi-proportional hazard model was used to predict OS, whereas the competing risks regression was used for predicting cancer-specific mortality (CSM). Results: The median (IQR) age for the patient population was 69 (63,74) years with a median (IQR) BMI of 28 (25-31) kg/m2. Of the 1577 patients included, 655 had died during foll...